Beijing YishengBio will merge with SPAC vehicle Summit Healthcare Acquisition to list on Nasdaq. Sihuan Pharma subsidiary Xuanzhu Biopharm has filed for an IPO on the Shanghai STAR Exchange.
invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical-stage company developing bispecific drugs for immunotherapies.